BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 27527602)

  • 21. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer.
    Cáceres-Gorriti KY; Carmona E; Barrès V; Rahimi K; Létourneau IJ; Tonin PN; Provencher D; Mes-Masson AM
    PLoS One; 2014; 9(3):e91000. PubMed ID: 24625450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
    Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
    Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying prognostic signature in ovarian cancer using DirGenerank.
    Wang JY; Chen LL; Zhou XH
    Oncotarget; 2017 Jul; 8(28):46398-46413. PubMed ID: 28615526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data.
    Bosquet JG; Marchion DC; Chon H; Lancaster JM; Chanock S
    Cancer Res; 2014 Jul; 74(14):3902-12. PubMed ID: 24848511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.
    Sallinen H; Janhonen S; Pölönen P; Niskanen H; Liu OH; Kivelä A; Hartikainen JM; Anttila M; Heinäniemi M; Ylä-Herttuala S; Kaikkonen MU
    BMC Cancer; 2019 Nov; 19(1):1121. PubMed ID: 31744494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome.
    Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A
    Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers.
    Huang RL; Gu F; Kirma NB; Ruan J; Chen CL; Wang HC; Liao YP; Chang CC; Yu MH; Pilrose JM; Thompson IM; Huang HC; Huang TH; Lai HC; Nephew KP
    Epigenetics; 2013 Jun; 8(6):624-34. PubMed ID: 23774800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome.
    Cai SY; Yang T; Chen Y; Wang JW; Li L; Xu MJ
    J Ovarian Res; 2015 Jul; 8():50. PubMed ID: 26228058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Kang J; D'Andrea AD; Kozono D
    J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validating the impact of a molecular subtype in ovarian cancer on outcomes: a study of the OVCAD Consortium.
    Pils D; Hager G; Tong D; Aust S; Heinze G; Kohl M; Schuster E; Wolf A; Sehouli J; Braicu I; Vergote I; Cadron I; Mahner S; Hofstetter G; Speiser P; Zeillinger R
    Cancer Sci; 2012 Jul; 103(7):1334-41. PubMed ID: 22497737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression profiling of epithelial ovarian cancer reveals key genes and pathways associated with chemotherapy resistance.
    Zhang M; Luo SC
    Genet Mol Res; 2016 Jan; 15(1):. PubMed ID: 26909918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
    Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
    Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 37. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer.
    Peng DX; Luo M; Qiu LW; He YL; Wang XF
    Oncol Rep; 2012 Apr; 27(4):1238-44. PubMed ID: 22246341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.
    Cheon DJ; Tong Y; Sim MS; Dering J; Berel D; Cui X; Lester J; Beach JA; Tighiouart M; Walts AE; Karlan BY; Orsulic S
    Clin Cancer Res; 2014 Feb; 20(3):711-23. PubMed ID: 24218511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of prognoses according to non-positive and positive spectrin αII expression detected immunohistochemically in epithelial ovarian carcinoma: a retrospective study.
    Maeda O; Miyata-Takata T; Shibata K; Kajiyama H; Mizuno M; Tamakoshi K; Shimoyama Y; Nakamura S; Kikkawa F
    Cancer Med; 2016 Jun; 5(6):1081-92. PubMed ID: 26993048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1.
    Khedkar HN; Wang YC; Yadav VK; Srivastava P; Lawal B; Mokgautsi N; Sumitra MR; Wu ATH; Huang HS
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.